



Newlook Capital Management



Elroy Gust
President & CEO

Elroy has over 20 years of experience in M&A and has completed over 25 transactions totaling over \$200 million.



Abbas Osman
Chief Investment Officer

Abbas has approximately 20 years of experience in M&A and has participated in over 100 transactions.



Tony Diab, CPA, CA
Chief Financial Officer

During his seven years as CFO, Tony has had critical involvement in acquisitions, financial oversight and fund management.



Gavin Treanor
VP External Sales

Gavin has 20 years of experience in commodity M&A and has been involved in over \$500 million in structured finance deals.



Oliver Blum
Managing Director

Oliver joined Newlook Capital in 2018 as the Fund Manager for Fund II.



Hass Keshavji
General Counsel

Hass joined Newlook in 2020 as Partner and General Counsel and has over 10 years of experience in M&A.

Risks

For a complete list of risks associated with this investment, including, but not limited to, investment risks, general economic risks, disease outbreak risks, business risks and industry risks, please refer to Item 10 – *Risk Factors* of the Offering Memorandum.

Redemptions Limitations

Please note that there is no guarantee that the redemption price will be the same as the purchase price. Redemption notes may be given for notices in excess of the aggregate quarterly cash limit of \$50,000, and redemption notes are not eligible to be held in exempt plans under the Income Tax Act. For more information, please refer to Item 2.7.1 *Declaration of Trust – Redemption of Trust Units* of the Offering Memorandum.

Period of time between the issuance and redemption	Series A	Series B	Series F
< 1 year	92.0%	89.0%	95.0%
1 year < 2 years	93.6%	91.0%	97.0%
2 years < 3 years	95.2%	93.0%	99.0%
3 years < 4 years	96.8%	95.0%	100%
4 years < 5 years	98.4%	97.0%	100%
5 years and greater	100%	100%	100%

Notes

- Source: IBISWorld Industry Report 62121CA Dentists in Canada, Aging teeth: The burgeoning elderly population will spur industry demand (August 2018).
- "Dentalook" means Dentalook Inc.
- Please refer to Item 2.7.1 – *Declaration of Trust - Redemption of Trust Units* of the Offering Memorandum for full details.
- The revenue and EBITDA amounts give effect to the acquisitions of the 19 clinics owned by Dentalook as at December 31, 2022 as if such acquisitions occurred at the beginning of 2019 and is derived from unaudited financial statements prepared by previous management of the 19 clinics.
- Production and EBITDA shown for 2020 reflects July to December 2020 run rate based on the 19 clinics owned by Dentalook as at December 31, 2022.
- Past performance is not indicative of future results. For illustration purposes only.

An offering memorandum dated May 29, 2023 (the "Offering Memorandum") containing important information relating to the securities described in this document has or will be filed with the securities regulatory authorities in each of the jurisdictions where a distribution has occurred or will occur pursuant to the Offering Memorandum. A copy of the Offering Memorandum is required to be delivered to you at the same time or before you sign the agreement to purchase the securities described in this document pursuant to the Offering Memorandum. This document does not provide disclosure of all information required for an investor to make an informed investment decision. Investors should read the entire Offering Memorandum of Newlook Capital Dental Services Trust, including, but not limited to the sections relating to: "Forward-Looking Information", "Risk Factors" and "Investor's Rights", before making an investment decision.